O-nitro compounds, pharmaceutical compositions thereof and uses thereof
The present invention provides O-nitro compound, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
1 . A method for treating or preventing cancer in a patient comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.
2 . The method of claim 1 in which the cancer is breast cancer, renal cancer, brain cancer, colon cancer, colorectal cancer, prostrate cancer, lung cancer, any other solid tumor or lymphohematopoietic malignancy.
3 . The method of claim 1 in which the O-nitro compound has the structure R 1 —O—NO 2 where R 1 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, fused cycloalkyl, substituted fused cycloalkyl, substituted cycloalkyl, fused cycloalkylcycloheteroalkyl, substituted fused cycloalkylcycloheteroalkyl, cubyl, substituted cubyl, adamantyl or substituted adamantyl.
4 . The compound of claim 3 in which R 1 —O—NO 2 has the structure:
wherein R 2 , R 3 , R 4 , R 5 and R 6 are independently hydrogen, alkyl or substituted alkyl.
5 . The compound of claim 3 in which R 1 —O—NO 2 has the structure:
6 . The compound of claim 3 in which R 1 —O—NO 2 has the structure:
7 . The compound of claim 3 in which R 1 —O—NO 2 has the structure:
wherein X is —S—, —O—, —N(R 7 ), —P(O)OR 7 , or —BR 7 where R 7 is hydrogen or alkyl.
8 . The compound of claim 3 in which R 1 —O—NO 2 has the structure:
wherein X is —S—, —O—, —N(R 7 ), —P(O)OR 7 , or —BR 7 where R 7 is hydrogen or alkyl.
9 . The compound of claim 3 in which R 1 —O—NO 2 has the structure:
10 . The compound of claim 3 in which R 1 —O—NO 2 has the structure:
11 . The compound of claim 3 in which R 1 —O—NO 2 has the structure:
12 . The compound of claim 3 in which R 1 —O—NO 2 has the structure:
wherein X is —S—, —O— or —N(R 7 ) where R 7 is hydrogen or alkyl.
13 . A pharmaceutical composition comprising an O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof and a pharmaceutically acceptable vehicle.
14 . A method for treating tumor cells with a reduced intracellular environment in a patient, comprising administering to the patient in need of treatment a therapeutically effective amount of an O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.
15 . A method for treating or preventing solid tumors in a patient, comprising administering to the patient in need of treatment or prevention a therapeutically effective amount of an O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.
16 . A method for treating or preventing inflammation in a patient, comprising administering to the patient in need of treatment or prevention a therapeutically effective amount an O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.
17 . A method for treating or preventing autoimmune disease in a patient, comprising administering to the patient in need of treatment or prevention a therapeutically effective amount of an O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.
18 . A method for treating or preventing cardiovascular disease in a patient, comprising administering to the patient in need of treatment or prevention a therapeutically effective amount an O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.